Want to see NAII full AI Analyst Report?
Top Page
Natural Alternatives International
(NASDAQ:NAII)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.00
▼(-36.51% Downside)
Action:Reiterated
Date:06/23/26
The score is primarily held down by weak financial performance—losses, negative operating/free cash flow, and higher leverage—alongside KPI evidence that the core contract manufacturing segment has become a volatile drag. Technicals add a secondary headwind as the stock sits below major moving averages with negative MACD, while valuation is only a modest offset because the negative P/E reflects ongoing losses and no dividend yield support is available.
Positive Factors
Proprietary ingredients & dual revenue streams
NAII benefits from a two-pronged business model: contract manufacturing and sales of the proprietary CarnoSyn® ingredient. This structural diversification supports recurring manufacturing revenue while licensing/ingredient sales provide higher-margin, IP-driven demand that can persist beyond short-term cycles.
Negative Factors
Weak profitability and margins
The company is operating at a sizeable net loss with very low gross margins, signaling structural pricing or cost issues in its core offerings. Persistent low gross margins constrain operating leverage and make it difficult to return to sustained profitability without material pricing, product mix, or cost-structure changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ingredients & dual revenue streams
NAII benefits from a two-pronged business model: contract manufacturing and sales of the proprietary CarnoSyn® ingredient. This structural diversification supports recurring manufacturing revenue while licensing/ingredient sales provide higher-margin, IP-driven demand that can persist beyond short-term cycles.
Read all positive factors
Natural Alternatives International Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much each business segment contributes to overall sales, indicating which areas drive growth and where diversification or expansion opportunities may exist.
Shows how much each business segment contributes to overall sales, indicating which areas drive growth and where diversification or expansion opportunities may exist.
Data provided by:
The Fly
The FlyNatural Alternatives International (NAII) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.99M
Dividend YieldN/A
Average Volume (3M)10.40K
Price to Earnings (P/E)―
Beta (1Y)0.07
Revenue Growth12.37%
EPS Growth-69.61%
CountryUS
Employees234
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-2.36
Shares Outstanding6,275,229
10 Day Avg. Volume14,152
30 Day Avg. Volume10,400
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.29
Price to Sales (P/S)0.15
P/FCF Ratio8.42
Enterprise Value/Market Cap5.13
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit7.23
Enterprise Value/Ebitda-37.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Natural Alternatives International Business Overview & Revenue Model
Company Description
Natural Alternatives International, Inc. (NAII) is a company dedicated to the global development, manufacturing, and marketing of nutritional supplements, with operations spanning the United States, Europe, Asia, and other international territorie...
How the Company Makes Money
NAII generates revenue primarily from two streams. (1) Contract manufacturing: NAII earns money by manufacturing dietary supplements for other companies under private-label/contract manufacturing arrangements. Revenue is recognized from the sale o...
Natural Alternatives International Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
48
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 140.99M | 129.86M | 113.80M | 154.01M | 170.97M | 178.52M |
| Gross Profit | 9.93M | 9.29M | 6.87M | 18.16M | 30.51M | 30.44M |
| EBITDA | -1.90M | -2.70M | -4.46M | 11.09M | 20.66M | 16.58M |
| Net Income | -14.37M | -13.57M | -7.22M | 2.52M | 10.71M | 10.77M |
Balance Sheet | ||||||
| Total Assets | 154.88M | 151.94M | 162.34M | 134.15M | 146.00M | 120.28M |
| Cash, Cash Equivalents and Short-Term Investments | 9.20M | 12.32M | 11.98M | 13.60M | 21.83M | 32.13M |
| Total Debt | 65.17M | 59.03M | 60.29M | 30.93M | 31.84M | 16.48M |
| Total Liabilities | 91.77M | 83.51M | 79.75M | 45.38M | 57.48M | 40.20M |
| Stockholders Equity | 63.11M | 68.43M | 82.59M | 88.77M | 88.52M | 80.08M |
Cash Flow | ||||||
| Free Cash Flow | -9.02M | 2.32M | -4.51M | -6.50M | -14.62M | 15.70M |
| Operating Cash Flow | -4.50M | 5.93M | -1.50M | 7.02M | 11.87M | 20.81M |
| Investing Cash Flow | -4.52M | -3.61M | -3.02M | -13.47M | -26.46M | -5.04M |
| Financing Cash Flow | 7.61M | -1.97M | 2.89M | -1.78M | 4.29M | -14.11M |
Natural Alternatives International Technical Analysis
Negative
3.15
Price Trends
2.53
Negative
2.62
Negative
2.97
Negative
Market Momentum
-0.08
Positive
26.74
Positive
13.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAII, the sentiment is Negative. The current price of 3.15 is above the 20-day moving average (MA) of 2.41, above the 50-day MA of 2.53, and above the 200-day MA of 2.97, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 26.74 is Positive, neither overbought nor oversold. The STOCH value of 13.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAII.
Natural Alternatives International Risk Analysis
Natural Alternatives International disclosed 22 risk factors in its most recent earnings report. Natural Alternatives International reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Natural Alternatives International Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $374.03M | 19.18 | 12.30% | ― | 7.26% | 104.70% | |
65 Neutral | $105.27M | 17.49 | 14.03% | ― | 42.27% | -33.19% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | $78.72M | 13.45 | 17.78% | 2.81% | -12.15% | -38.04% | |
54 Neutral | $405.82M | 46.25 | 1.66% | ― | 5.67% | -73.96% | |
45 Neutral | $51.04M | -0.10 | -140.70% | ― | -10.00% | -98.14% | |
44 Neutral | $13.99M | -0.96 | -17.43% | ― | 12.37% | -69.61% |
* Consumer Defensive Sector Average
NAII
Natural Alternatives International
2.23
-1.17
-34.41%
NATR
Nature's Sunshine Products
21.27
5.48
34.71%
HAIN
Hain Celestial
0.57
-1.05
-64.91%
USNA
USANA Health
21.98
-10.61
-32.56%
LFVN
LifeVantage
6.24
-5.82
-48.25%
FTLF
FitLife Brands
11.21
-1.88
-14.36%
Natural Alternatives International Corporate Events
Executive/Board Changes
Natural Alternatives International Announces CFO Leadership Transition
Neutral
May 1, 2026
Natural Alternatives International announced that Chief Financial Officer Michael E. Fortin has resigned, effective May 15, 2026, to take a CFO role at another company offering greater responsibilities and professional growth. During the search fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.